**Figure 1** Comparison of left ventricular functional and dimensional parameters between treated and control groups in patients with cardiomyopathy

|  |  |
| --- | --- |
| Изображение | Изображение |
| Изображение | |

CM Cardiomyopathy

LVEF left ventricle ejection fraction

LVEDD left ventricle end-diastolic diameter

LVEDV left ventricle end-diastolic volume

BL 0 FU - baseline Follow-Up (FU) at admission and ACM starting,

BL 1 - Baseline time at PAB application

FU 1 - 1 month after PAB

FU 2 - 2 month after PAB

FU 3 - 3 months after PAB

FU 4 - 1 year after PAB

FU 5 - 5 years after PAB

ACM: Anti-congestion medication  
PAB: Pulmonary artery banding

**Figure 2** Comparison of left ventricular functional and dimensional parameters between treated and control groups in patients with LVNC

|  |  |
| --- | --- |
| Изображение | Изображение |
| Изображение | |

LVEF left ventricle ejection fraction

LVEDD left ventricle end-diastolic diameter

LVEDV left ventricle end-diastolic volume

LVNC: Left ventricular noncompaction cardiomyopathy

BL 0 FU - baseline Follow-Up (FU) at admission and ACM starting,

BL 1 - Baseline time at PAB application

FU 1 - 1 month after PAB

FU 2 - 2 month after PAB

FU 3 - 3 months after PAB

FU 4 - 1 year after PAB

FU 5 - 5 years after PAB

ACM: Anti-congestion medication  
PAB: Pulmonary artery banding